여성 건강 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Womens Health Market size is expected to reach USD 49.93 Billion in 2034 from USD 30.39 Billion (2025) growing at a CAGR of 5.67% during 2026-2034.

The global women's health market is experiencing steady growth due to increasing awareness of gender-specific healthcare needs and the rising prevalence of conditions such as breast cancer, osteoporosis, and reproductive health disorders. Governments and healthcare organizations are focusing more on preventive care, early diagnosis, and specialized treatment options designed specifically for women. Growing healthcare investments and improved access to medical services are also supporting the expansion of women's health solutions worldwide.

One of the key drivers of this market is the growing demand for advanced diagnostic and therapeutic technologies related to reproductive health and maternal care. The rising use of contraceptives, fertility treatments, and menopause management therapies is also contributing to market growth. Additionally, technological advancements in medical devices and digital health platforms are enabling better monitoring and treatment of women's health conditions.

Looking ahead, the women's health market is expected to grow significantly as awareness campaigns and healthcare initiatives continue to expand globally. Advances in biotechnology, personalized medicine, and digital healthcare solutions will further improve treatment options. With increasing research focused on women-specific conditions, the market is likely to witness sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Hormonal Infertility
• Contraceptives
• Postmenopausal Osteoporosis
• Endometriosis & Uterine Fibroids
• Menopause
• Polycystic Ovary Syndrome (PCOS)

By Drug Class

• Hormonal Therapies
• Bone Health Agents
• Fertility Agents
• GnRH Modulators
• Pain and Symptom Management
• Metabolic Agents
• Others

COMPANIES PROFILED

• AbbVie Inc, Bayer AG, Merck Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics, Amgen Inc, Apothecus Pharmaceutical Corp, Blairex Laboratories Inc, Ferring BV
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL WOMENS HEALTH MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Hormonal Infertility Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Postmenopausal Osteoporosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Endometriosis & Uterine Fibroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Menopause Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Polycystic Ovary Syndrome (PCOS) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL WOMENS HEALTH MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Hormonal Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Bone Health Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Fertility Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. GnRH Modulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Pain and Symptom Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Metabolic Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL WOMENS HEALTH MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Application
  • 6.2.2 By Drug Class
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Application
  • 6.3.2 By Drug Class
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Application
  • 6.4.2 By Drug Class
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Application
  • 6.5.2 By Drug Class
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Application
  • 6.6.2 By Drug Class
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL WOMENS HEALTH INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AbbVie Inc
  • 8.2.2 Bayer AG
  • 8.2.3 Merck & Co. Inc
  • 8.2.4 Pfizer Inc
  • 8.2.5 Teva Pharmaceutical Industries Ltd
  • 8.2.6 Agile Therapeutics
  • 8.2.7 Amgen Inc
  • 8.2.8 Apothecus Pharmaceutical Corp
  • 8.2.9 Blairex Laboratories Inc
  • 8.2.10 Ferring B.V